(Total Views: 393)
Posted On: 01/27/2021 9:57:24 AM
Post# of 72441
A new SOC?
https://www.usatoday.com/story/news/health/20...263087001/
Brilacidin will need to demonstrate competitive numbers.
A reduction in length of infection along with Bs 3 pronged attack on COVID; antiviral, anti inflammatory, anti bacterial to combat secondary infection will define value. Hopefully B can demonstrate a significant reduction in viral load. Additionally, B should prove cheaper and easier to produce in mass quantities than a monoclonal-antibody treatment.
https://www.usatoday.com/story/news/health/20...263087001/
Brilacidin will need to demonstrate competitive numbers.
A reduction in length of infection along with Bs 3 pronged attack on COVID; antiviral, anti inflammatory, anti bacterial to combat secondary infection will define value. Hopefully B can demonstrate a significant reduction in viral load. Additionally, B should prove cheaper and easier to produce in mass quantities than a monoclonal-antibody treatment.
(0)
(0)Scroll down for more posts ▼
